Positive 3-year results from the phase III PHOTON study were presented at the recent American Academy of Ophthalmology (AAO) ...

In a phase 2 trial, a gene therapy reduced angioedema attacks, which could significantly change the quality of life for patients with hereditary angioedema.

Emmecell announced positive Phase 1 extension study results for EO2002, a nonsurgical cell therapy for corneal edema. The ...

Cohort receiving 150,000 cells achieved 11-letter mean change in best corrected visual acuity (BCVA) at 6 months, ...

Gwen Brewer shares how she was able to reverse Type 2 diabetes and save her eyesight from DME by participating in a clinical ...

About ORLADEYO® (berotralstat) ORLADEYO ® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 ...

With unfortunately no curative therapy for chronic spontaneous urticaria (CSU) available for now, the overall goal is to ...

Intellia's Phase 3 trial for NTLA-2002 shows promise, but limitations warrant caution. See why we believe NTLA stock is hold ...

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Hereditary Angioedema Market Size in the 7MM is expected to Grow by 2034, estimates DelveInsight ...

RevOpsis says it is committed to the rapid discovery and development of novel multispecific therapies utilizing its modular ...

showing dramatic reductions of angioedema swellings following a single-dose treatment with this gene editing-based therapy," says Danny Cohn, internist at Amsterdam UMC and first author of the study.

FDA approval of MIPLYFFA™ and product launch cap third quarter filled with multiple commercial and clinical development milestonesZevra received ...